MET and neoplasm: Although the strategy of developing tyrosine kinase inhibitors with unrivalled specificity towards c-Met offers theoretical advantages in limiting the confounding issue of off-target toxicity and could specifically achieve the therapeutic potential of c-Met inhibition alone, it is possible that many such compounds will have limited efficacy as single-agent therapies, due in part to the development of drug-resistant mutations in tumor cell lines.